May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Ocular Pharmacokinetics of Besifloxacin, a Novel Fluoroquinolone Antimicrobial Agent for Topical Ophthalmic Use, in Healthy Volunteers
Author Affiliations & Notes
  • C. Granvil
    Global Research & Development, Bausch & Lomb, Rochester, New York
  • R. Siou-Mermet
    Global Research & Development, Bausch & Lomb, Rochester, New York
  • T. Comstock
    Global Research & Development, Bausch & Lomb, Rochester, New York
  • M. Jonasse
    Global Research & Development, Bausch & Lomb, Rochester, New York
  • J. Proksch
    Global Research & Development, Bausch & Lomb, Rochester, New York
  • Footnotes
    Commercial Relationships  C. Granvil, Bausch & Lomb, F; R. Siou-Mermet, Bausch & Lomb, F; T. Comstock, Bausch & Lomb, F; M. Jonasse, Bausch & Lomb, F; J. Proksch, Bausch & Lomb, F.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 873. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. Granvil, R. Siou-Mermet, T. Comstock, M. Jonasse, J. Proksch; Ocular Pharmacokinetics of Besifloxacin, a Novel Fluoroquinolone Antimicrobial Agent for Topical Ophthalmic Use, in Healthy Volunteers. Invest. Ophthalmol. Vis. Sci. 2008;49(13):873. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess the ocular pharmacokinetics (PK) of besifloxacin, a novel fluoroquinolone in clinical development for bacterial conjunctivitis, following single topical ocular administration to healthy volunteers. The PK data were used along with in vitro antimicrobial MIC90 values for besifloxacin to assess the clinical PK/PD relationship for this anti-infective.

Methods: : Sixty four healthy subjects were enrolled in this open-label study. Subjects received a single instillation of besifloxacin hydrochloride ophthalmic suspension (0.6% as free base) in the conjunctival sac of each eye. A single tear sample was collected on Schirmer tear strips from each subject at a predetermined time point with samples collected from separate groups over the 24 h after dosing. Besifloxacin concentrations in tear samples were analyzed by LC/MS/MS.

Results: : Following a single topical ocular dose, maximal besifloxacin concentrations in tears were observed within 10 min (Cmax of 610 ± 540 µg/g). Concentrations of 1.5 µg/g or higher were sustained for at least 24 h after dosing. Total exposure to besifloxacin in tears, based on AUC(0-24 h), was 1232 µg*h/g. Elimination of besifloxacin from tears occurred with an estimated half-life of 3.4 h. Both Cmax/MIC90 and AUC0-24h/MIC90 ratios were in excess of the minimum values associated with bacterial eradication against Staphylococcus aureus or Haemophilus influenzae. Results from PK modeling indicated that a TID dosing regimen would provide additional coverage and an improved PK/PD profile against other microorganisms.

Conclusions: : Besifloxacin ophthalmic suspension afforded high besifloxacin concentrations in tears that were sustained for at least 24 h after a single dose. The combination of broad spectrum antimicrobial activity and PK/PD properties of besifloxacin support the continued clinical evaluation of besifloxacin for the treatment of bacterial conjunctivitis.

Clinical Trial: : www.clinicaltrials.gov NCT00407589

Keywords: conjunctivitis • clinical (human) or epidemiologic studies: biostatistics/epidemiology methodology • antibiotics/antifungals/antiparasitics 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×